Felycin™-CA1 (Sirolimus Delayed-Release Tablets) is the first FDA
conditionally approved medication specifically developed to manage
feline hypertrophic cardiomyopathy (HCM). Formulated for oral use in
cats, Felycin™-CA1 contains sirolimus, which helps regulate pathways
involved in abnormal heart muscle thickening. This prescription
medication offers a new approach to feline cardiac care, improving
treatment consistency and compliance.

▪First FDA conditionally approved treatment for feline HCM
▪Delayed-release tablets formulated for cats
▪Contains sirolimus to target heart muscle abnormalities
▪Oral administration supports at-home use
▪Designed to improve quality of life in cats with hypertrophic
cardiomyopathy